Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 89% Improvement Relative Risk Case 28% Fromonot et al. Zinc for COVID-19 Sufficiency Are zinc levels associated with COVID-19 outcomes? Prospective study of 240 patients in France Lower hospitalization (p=0.002) and fewer cases (p=0.003) Fromonot et al., Clinical Nutrition, doi:10.1016/j.clnu.2021.04.042 Favors zinc Favors control
Hypozincemia in the early stage of COVID-19 is associated with an increased risk of severe COVID-19
Fromonot et al., Clinical Nutrition, doi:10.1016/j.clnu.2021.04.042
Fromonot et al., Hypozincemia in the early stage of COVID-19 is associated with an increased risk of severe COVID-19, Clinical Nutrition, doi:10.1016/j.clnu.2021.04.042
May 2021   Source   PDF  
  All Studies   Meta
Analysis of 240 consecutive patients in France, showing significantly higher zinc deficiency in COVID-19 patients, and significantly greater risk of hospitalization for COVID-19 patients with zinc deficiency. 2020PI087.
risk of hospitalization, 89.2% lower, RR 0.11, p = 0.002, high zinc levels 6 of 110 (5.5%), low zinc levels 7 of 42 (16.7%), NNT 8.9, inverted to make RR<1 favor high zinc levels, odds ratio converted to relative risk, within COVID-19 patients.
risk of case, 27.6% lower, RR 0.72, p = 0.003, high zinc levels 110 of 188 (58.5%), low zinc levels 42 of 52 (80.8%), NNT 4.5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fromonot et al., 3 May 2021, prospective, France, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: Clinical Nutrition xxx (xxxx) xxx Contents lists available at ScienceDirect Clinical Nutrition journal homepage: Short Communication Hypozincemia in the early stage of COVID-19 is associated with an increased risk of severe COVID-19 ant c, Julien Fromonot a, b, *, Mickael Gette a, Amin Ben Lassoued a, Jean-Louis Gue gis Guieu a, b ant-Rodriguez c, Re Rosa-Maria Gue a Service de Biochimie, Timone University Hospital, AP-HM, Marseille, France Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France Department Inserm, UMR_S 1256, Nutrition-Genetics-Environmental Risk Exposure, Universit e de Lorraine and University Regional hospital of Nancy, Nancy, France b c a r t i c l e i n f o s u m m a r y Article history: Received 9 October 2020 Accepted 21 April 2021 Background & aims: Nutritional predisposition to severe coronavirus disease 2019 (COVID-19) remains unclear. Zinc deficiency could be critical since it is associated with a higher susceptibility to infections. We evaluated the prevalence of hypozincemia in the early stage of COVID-19, its association with risk factors for severe COVID-19 and its prognostic value for hospitalization for respiratory complications within 10 days. Methods: For 152 COVID-19 patients and 88 non-COVID-19 patients admitted to COVID-19 screening centers, national early warning score for COVID-19 (NEWS) and laboratory analyses were performed to identify the risk for severe COVID-19. Multivariable logistic regression analysis assessed whether hypozincemia was an independent predictor of hospitalization for respiratory complications within 10 days (primary judgment criterion). The secondary judgment criteria were high NEWS score (7), comorbidities and biomarkers associated with severe COVID-19. Results: Hypozincemia was more frequent in COVID-19 patients compared to non-COVID-19 patients (27.6% vs 11.4%; p ¼ 0.003). Older patients (65 years) and medically assisted nursing home residents were at higher risk of hypozincemia (p < 0.01). Hypozincemia was associated with a worse NEWS score (p < 0.01) and lymphopenia (p < 0.001). Hypozincemia was independently associated with hospitalization for respiratory complications within 10 days (OR ¼ 10.9, 95% CI ¼ 2.3e51.6, p ¼ 0.002). Conclusions: In the early stage of COVID-19, the prevalence of hypozincemia exceeded 20%. Hypozincemia was an independent predictor of hospitalization for respiratory complications within 10 days. This may suggest the importance of early detection and treatment of zinc deficiency in the nutritional management of COVID-19, especially in older people. Therefore, intervention and adjuvant treatment trials are strongly needed. © 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. Keywords: COVID-19 Zinc Selenium Risk factor Lymphopenia Inflammation
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop